billHR7767Event Tuesday, March 3, 2026Analyzed

Make Billionaires Pay Their Fair Share Act

Neutral
Impact3/10

Summary

HR7767, the "Make Billionaires Pay Their Fair Share Act," was introduced in the House on March 3, 2026, and referred to four committees. The bill proposes an annual tax on the net value of assets held by taxpayers, with proceeds intended for affordability rebates, healthcare expansions, a housing trust fund, childcare, and teacher salaries. No specific funding amounts are authorized or appropriated within the provided text.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR7767, proposing an annual wealth tax, is in the early committee referral stage in the House.
  • 2.The bill outlines broad spending initiatives across healthcare, housing, childcare, and education, contingent on the implementation of a wealth tax.
  • 3.No specific funding amounts are authorized or appropriated within the current bill text, making direct financial impact on companies speculative at this stage.

Market Implications

The "Make Billionaires Pay Their Fair Share Act" is currently in the initial stages of the legislative process, having been referred to multiple House committees. The primary market implication, if the bill were to advance, would be a structural change in taxation for high-net-worth individuals, potentially affecting capital allocation and investment strategies within the Finance sector. The bill's proposed spending on healthcare, housing, childcare, and education could create new demand or funding streams in those sectors, but these are contingent on the wealth tax's implementation and subsequent appropriations. As no specific tax rates or spending amounts are defined, and the bill is far from enactment, there is no immediate, direct market impact on specific tickers. The bill's progression would need to be monitored for detailed provisions that could create clear winners or losers.

Full Analysis

HR7767, titled the "Make Billionaires Pay Their Fair Share Act," was introduced in the House of Representatives on March 3, 2026, by Rep. Khanna. The bill is currently in the early stages of the legislative process, having been referred to the Committees on Ways and Means, Energy and Commerce, Financial Services, and Education and Workforce. This referral to multiple committees indicates a broad scope and the need for review across various jurisdictions. The core of the bill, Title I, proposes to amend the Internal Revenue Code of 1986 to impose an annual tax on the net value of assets held by a taxpayer. The subsequent titles outline the intended uses of the revenue generated from this wealth tax, including affordability rebates (Title II), health care provisions such as repealing reconciliation health provisions and increasing eligibility for premium tax credits (Title III), Medicare dental, hearing, and vision expansion (Title IV), a housing trust fund (Title V), affordable childcare (Title VI), a minimum salary for public school teachers (Title VII), and investments in home and community-based services and long-term care (Title VIII). The bill text does not specify any dollar amounts for the proposed wealth tax rate or the funding for the various programs it aims to support; it primarily establishes the framework for these initiatives. As the bill is in the early committee referral stage, there are no direct appropriations or authorizations of specific dollar amounts for the programs outlined. The mechanism for funding these initiatives would be through the proposed wealth tax, which would require subsequent legislative action to define its specifics and implement. The bill's broad scope touches upon various sectors, including finance due to the wealth tax, healthcare through Medicare expansion and premium tax credits, real estate via the housing trust fund, and consumer and education sectors through childcare and teacher salary provisions. Given the early stage and the nature of the proposed tax, there are no immediate direct beneficiaries or losers among publicly traded companies at this juncture. The bill's progression would need to include detailed tax rates and spending allocations to identify specific market impacts. No recent presidential actions directly amplify or conflict with this specific legislative proposal. The recent Presidential Memoranda on the Defense Production Act focus on energy and infrastructure, which are distinct from the tax and social spending proposals in HR7767. The legislative path for HR7767 involves consideration by the four referred committees. Each committee will review the provisions falling within its jurisdiction. Further action, such as committee markups or votes, would be required for the bill to advance to a floor vote in the House.

Market Impact Score

3/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

presidential_memorandumApr 20, 2026

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Development, Manufacturing, and Deployment of Large-Scale Energy and Energy‑Related Infrastructure

This presidential memorandum invokes Section 303 of the Defense Production Act (DPA) to accelerate the development, manufacturing, and deployment of large-scale energy and energy-related infrastructure. It authorizes the Secretary of Energy to make necessary purchases, commitments, and financial instruments to expand domestic capabilities in this sector, citing a national energy emergency and the need to avert an industrial resource shortfall.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.